IDEAYA Biosciences, Inc. (FRA:30J)

Market Cap	2.38B +21.6%
Revenue (ttm)	183.10M +5,377.7%
Net Income	-137.00M
EPS	-1.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	27.80
Previous Close	28.80
Day's Range	27.80 - 27.80
52-Week Range	12.80 - 32.20
Beta	n/a
RSI	37.25
Earnings Date	Feb 13, 2026

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene de...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 131
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30J

Financial Performance

In 2024, IDEAYA Biosciences's revenue was $7.00 million, a decrease of -70.07% compared to the previous year's $23.39 million. Losses were -$274.48 million, 143.0% more than in 2023.

Financial numbers in USD